FilingReader Intelligence
Wockhardt exits US generics after $8m losses
July 11, 2025 at 10:59 AM UTC•By FilingReader AI
Wockhardt is exiting the US generic pharmaceutical segment after losses of nearly $8 million in FY 2025. The company will liquidate Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC under Chapter 7 bankruptcy by July 11, 2025.
Wockhardt will now focus on new antibiotic drug discovery and its biologicals portfolio in insulin.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:WOCKPHARMA•Bombay Stock Exchange
News Alerts
Get instant email alerts when Wockhardt publishes news
Free account required • Unsubscribe anytime